pProvector_AAV2_586_PLGLAR
(Plasmid
#129024)
-
PurposeRecombinant AAV2 rep/cap plasmid modified to include an 18 amino acid peptide at cap position 586.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 129024 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneunknown
- Total vector size (bp) 7342
-
Vector typeAAV
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameRep2/Cap2 with PLGLAR lock at 586
-
SpeciesSynthetic; AAV
-
Mutationinserted peptide motif (PLGLARGDDDDGPLGLAR) at position 586
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pProvector_AAV2_586_PLGLAR was a gift from Junghae Suh (Addgene plasmid # 129024 ; http://n2t.net/addgene:129024 ; RRID:Addgene_129024) -
For your References section:
Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform. Tong JG, Evans AC, Ho ML, Guenther CM, Brun MJ, Judd J, Wu E, Suh J. J Control Release. 2019 Jun 25. pii: S0168-3659(19)30367-0. doi: 10.1016/j.jconrel.2019.06.034. 10.1016/j.jconrel.2019.06.034 PubMed 31252037